162 related articles for article (PubMed ID: 31807974)
1. Hypogonadism and prostate cancer detection on multiparametric MRI and mpMRI-TRUS fusion biopsy.
Sugano D; Sidana A; Jain AL; Calio B; Gaur S; Maruf M; Merino M; Choyke P; Turkbey B; Wood BJ; Pinto PA
Int Urol Nephrol; 2020 Apr; 52(4):633-638. PubMed ID: 31807974
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
[TBL] [Abstract][Full Text] [Related]
3. Multiparametric magnetic resonance imaging (MRI) and subsequent MRI/ultrasonography fusion-guided biopsy increase the detection of anteriorly located prostate cancers.
Volkin D; Turkbey B; Hoang AN; Rais-Bahrami S; Yerram N; Walton-Diaz A; Nix JW; Wood BJ; Choyke PL; Pinto PA
BJU Int; 2014 Dec; 114(6b):E43-E49. PubMed ID: 24712649
[TBL] [Abstract][Full Text] [Related]
4. Changes in prostate cancer detection rate of MRI-TRUS fusion vs systematic biopsy over time: evidence of a learning curve.
Calio B; Sidana A; Sugano D; Gaur S; Jain A; Maruf M; Xu S; Yan P; Kruecker J; Merino M; Choyke P; Turkbey B; Wood B; Pinto P
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):436-441. PubMed ID: 28762373
[TBL] [Abstract][Full Text] [Related]
5. Midline lesions of the prostate: role of MRI/TRUS fusion biopsy and implications in Gleason risk stratification.
Muthigi A; Sidana A; George AK; Kongnyuy M; Shakir N; Kadakia M; Maruf M; Frye TP; Mertan F; Su D; Merino MJ; Choyke PL; Turkbey B; Wood BJ; Pinto PA
Int Urol Nephrol; 2016 Sep; 48(9):1445-52. PubMed ID: 27305918
[TBL] [Abstract][Full Text] [Related]
6. Comparison of free-hand transperineal mpMRI/TRUS fusion-guided biopsy with transperineal 12-core systematic biopsy for the diagnosis of prostate cancer: a single-center prospective study in China.
Zhang Q; Wang W; Zhang B; Shi J; Fu Y; Li D; Guo S; Zhang S; Huang H; Jiang X; Zhou W; Guo H
Int Urol Nephrol; 2017 Mar; 49(3):439-448. PubMed ID: 28005230
[TBL] [Abstract][Full Text] [Related]
7. Incremental diagnostic value of targeted biopsy using mpMRI-TRUS fusion versus 14-fragments prostatic biopsy: a prospective controlled study.
Mariotti GC; Falsarella PM; Garcia RG; Queiroz MRG; Lemos GC; Baroni RH
Eur Radiol; 2018 Jan; 28(1):11-16. PubMed ID: 28687911
[TBL] [Abstract][Full Text] [Related]
8. Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis.
Sidana A; Watson MJ; George AK; Rastinehad AR; Vourganti S; Rais-Bahrami S; Muthigi A; Maruf M; Gordetsky JB; Nix JW; Merino MJ; Turkbey B; Choyke PL; Wood BJ; Pinto PA
Urol Oncol; 2018 Jul; 36(7):341.e1-341.e7. PubMed ID: 29753548
[TBL] [Abstract][Full Text] [Related]
9. Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL.
Lee DH; Nam JK; Park SW; Lee SS; Han JY; Lee SD; Lee JW; Chung MK
Yonsei Med J; 2016 May; 57(3):565-71. PubMed ID: 26996553
[TBL] [Abstract][Full Text] [Related]
10. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.
Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Pennisi M; Morgia G
Scand J Urol; 2017 Aug; 51(4):260-263. PubMed ID: 28513296
[TBL] [Abstract][Full Text] [Related]
11. Multiparametric MRI guidance in first-time prostate biopsies: what is the real benefit?
Acar Ö; Esen T; Çolakoğlu B; Vural M; Onay A; Sağlıcan Y; Türkbey B; Rozanes İ
Diagn Interv Radiol; 2015; 21(4):271-6. PubMed ID: 26027768
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis.
Choi YH; Kang MY; Sung HH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Kim CK; Park BK; Lee HM
Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878
[TBL] [Abstract][Full Text] [Related]
13. There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies.
Dell'Oglio P; Stabile A; Soligo M; Brembilla G; Esposito A; Gandaglia G; Fossati N; Bravi CA; Dehò F; De Cobelli F; Montorsi F; Karnes RJ; Briganti A
Eur Urol Oncol; 2020 Feb; 3(1):112-118. PubMed ID: 31411973
[TBL] [Abstract][Full Text] [Related]
14. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
15. Role of Systematic Control Biopsies following Partial Gland Ablation with High-Intensity Focused Ultrasound for Clinically Significant Prostate Cancer.
Rompré-Brodeur A; Marcq G; Tholomier C; Fugaru I; Loutochin O; Anidjar M; Bladou F
J Urol; 2021 Nov; 206(5):1177-1183. PubMed ID: 34251879
[TBL] [Abstract][Full Text] [Related]
16. Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer.
Panebianco V; Valerio MC; Giuliani A; Pecoraro M; Ceravolo I; Barchetti G; Catalano C; Padhani AR
Eur Urol Oncol; 2018 Aug; 1(3):208-214. PubMed ID: 31102623
[TBL] [Abstract][Full Text] [Related]
17. A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI).
Gaur S; Harmon S; Gupta RT; Margolis DJ; Lay N; Mehralivand S; Merino MJ; Wood BJ; Pinto PA; Shih JH; Choyke PL; Turkbey B
Acad Radiol; 2019 Jan; 26(1):5-14. PubMed ID: 29705281
[TBL] [Abstract][Full Text] [Related]
18. Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy.
Muthigi A; George AK; Sidana A; Kongnyuy M; Simon R; Moreno V; Merino MJ; Choyke PL; Turkbey B; Wood BJ; Pinto PA
J Urol; 2017 Feb; 197(2):327-334. PubMed ID: 27582434
[TBL] [Abstract][Full Text] [Related]
19. Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging.
Chaloupka M; Bischoff R; Pfitzinger P; Lellig E; Ledderose S; Buchner A; Schlenker B; Stief C; Clevert DA; Apfelbeck M
Clin Hemorheol Microcirc; 2019; 73(1):105-111. PubMed ID: 31561351
[TBL] [Abstract][Full Text] [Related]
20. "In-bore" MRI prostate biopsy is a safe preoperative clinical tool to exclude significant prostate cancer in symptomatic patients with benign prostatic obstruction before transurethral laser enucleation.
Porreca A; D'Agostino D; Vigo M; Corsi P; Romagnoli D; Del Rosso A; Schiavina R; Brunocilla E; Artibani W; Giampaoli M
Arch Ital Urol Androl; 2020 Jan; 91(4):224-229. PubMed ID: 31937084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
